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Abstract. This report summarizes the design and outcomes of randomized controlled operational research trials
performed by the Bill & Melinda Gates Foundation–funded Schistosomiasis Consortium for Operational Research and
Evaluation (SCORE) from2009 to 2019. Their goal was to define the effectiveness and test the limitations of currentWHO-
recommended schistosomiasis control protocols by performing large-scale pragmatic trials to compare the impact of
different schedules and coverage regimens of praziquantel mass drug administration (MDA). Although there were limi-
tations to study designs and performance, analysis of their primary outcomes confirmed that all tested regimens of
praziquantelMDAsignificantly reduced localSchistosoma infection prevalence and intensity amongschool-age children.
Secondary analysis suggested that outcomes in locations receiving four annual rounds of MDAwere better than those in
communities that had treatment holiday years, in which no praziquantel MDA was given. Statistical significance of
differences was obscured by a wider-than-expected variation in community-level responses to MDA, defining a per-
sistent hot spot obstacle to MDA success. No MDA schedule led to elimination of infection, even in those communities
that started at low prevalence of infection, and it is likely that programs aiming for elimination of transmission will need to
add supplemental interventions (e.g., snail control, improvement in water, sanitation and hygiene, and behavior change
interventions) to achieve that next stage of control. Recommendations for future implementation research, including
exploration of the value of earlier program impact assessment combined with intensification of intervention in hot spot
locations, are discussed.
INTRODUCTION
In 2009, theBill &MelindaGates Foundation (BMGF) funded
the Schistosomiasis Consortium for Operational Research
and Evaluation (SCORE), based at the University of Georgia.
The seven most extensive projects at the core of SCORE’s
operational research agenda involved large-scale, random-
ized comparison trials of different approaches to mass drug
administration (MDA) using praziquantel for control of either
Schistosoma mansoni or of Schistosoma haematobium in
endemic areas of sub-Saharan Africa.1 In aiming to provide
programmanagers and policymakerswith better evidence for
decision-making, SCORE’s research objective for these
studies was to generate data on the relative effectiveness of
community-wide treatment (CWT) versus school-based
treatment (SBT)2,3 and on the relative effectiveness of annual
praziquantel drug delivery as compared with schedules that
involve holiday years—that is, years without praziquantel
MDA.4–8 The focus on sub-Saharan Africa was based on this
region having the greatest burden of schistosomiasis globally
and the greatest need for information about optimal imple-
mentations at national and subnational scales.
After extensive consultation in 2009 with program man-
agers, field trial researchers, biostatisticians, and represen-
tatives of the WHO, SCORE designed multiyear, large-scale
cluster-randomized trials to study options for program
implementation in areas having ³ 10% Schistosoma infection
prevalence among school-age children (SAC).1 At the time,
WHOguidelines recommendedevery-other-year praziquantel
treatment of all SAC in communities having SAC prevalence
between 10% and 49%, and annual SAC treatment for com-
munities having SACprevalence ³ 50%.9 For both categories,
concurrent treatment of high-risk adults (i.e., those having
regular contact with infested water, such as fishermen, farm-
ers, irrigation workers, or women regularly coming in contact
as part of their domestic tasks) was recommended, with the
added proviso that in the areas of highest prevalence (³ 50%),
the entire community might need to be treated.9
In 2009, SCORE stakeholder partner deliberations agreed
that these existing thresholds for implementation of mass
treatment needed refinement and a better evidence base to
establish the relative benefits of different age-group coverage
formats anddifferent schedules of targetedmasspraziquantel
delivery.1 In particular, it seemed quite unlikely that commu-
nities starting at a prevalence of 10% Schistosoma infection
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would have the same response to mass treatment as com-
munities starting at a several fold higher prevalence (e.g.,
49%), although they were classified in the same risk group by
WHO guidelines.9 There was interest in finding out whether,
when compared with SBT, using one or more years of CWT
would have agreater impact on theprevalence and intensity of
infection if, for example, CWT could achieve better coverage
of SACwho did not attend school2 or better coverage of high-
risk adults. There also was a lack of data as to whether every-
other-year delivery of MDA could be “good enough” for
morbidity control,10 that is, near elimination of heavy infec-
tions (defined as ³ 400 S. mansoni eggs per gram of stool or
³ 50 S. haematobium eggs per 10 mL of urine).9
As a result, two types of SCORE treatment trials were de-
veloped to focus separately on communities having starting
prevalence 10–24%, designated as sustaining control stud-
ies, and on communities having starting prevalence ³ 25%,
designated as gaining control studies. Sustaining control
studies in S. mansoni areas were conducted in Coˆte d’Ivoire
and in western Kenya. Gaining control studies in S. mansoni
areas were performed in Kenya and in Tanzania, and a gaining
control study was performed in Mozambique in an area en-
demic for S. haematobium.1 Niger began both gaining and
sustaining control studies in areas endemic forS. haematobium.
However, these studies had then to be modified, as detailed in
the following paragraphs.
This article summarizes the results of the SCORE gaining
and sustaining studies and the redesigned Niger study. A
separate report in this issue11 presents the results of separate
SCORE studies that focused on “moving toward elimination”
on Zanzibar and in S. haematobium–endemic areas of north-
ern and central Coˆte d’Ivoire.12
SCHISTOSOMIASIS CONSORTIUM FOR OPERATIONAL
RESEARCH AND EVALUATION STUDY DESIGNS
Development of harmonized protocols for the SCORE
gaining and sustaining control studies has been described
in detail in a previous publication.1 Briefly, it was decided
that sustaining control studies (in locations with starting
Schistosoma prevalence of 10–24%) would have community-
level randomization to one of three different arms that
compared different schedules of SBTwith praziquantel. The
higher prevalence gaining control areas were believed to
need more aggressive intervention, but there was consid-
erable uncertainty (and therefore equipoise) about whether
more aggressive population coverage ormore frequent drug
delivery would yield better outcomes in terms of reducing
prevalence and intensity of Schistosoma infection.1 There-
fore, communities in the gaining control studies (starting
prevalence ³ 25%) were randomized to one of six arms: the
three SBT schedules used in the sustaining control studies,
plus three additional arms that included CWT. A diagram
of the treatments given in the different study arms of
the gaining and sustaining control studies is presented in
Figure 1.
The studies were unblinded, community-level, cluster-
randomized control trials, with communities receiving either
CWT, SBT, or a CWT to SBT transition, with or without pra-
ziquantel holidays during the 4 years of trial. Although all
school-age children were targeted for MDA, the chosen
study endpoints were based on the evaluation of infection
prevalence and intensity outcomes among 9–12-year-old
children, the highest risk group, in each community in Year 5.
Community eligibility was determined by initial preenrollment
screening surveys forS.mansoni orS. haematobium infection
among fifty 13–14-year-old schoolchildren. This screening
age range was chosen for the community eligibility assess-
ment because, ethically, it was felt that any child diagnosed as
infected with schistosomes deserved prompt individual
treatment and that pre-study treatment of a small number of
13–14-year-old individuals would not influence the underlying
community baseline status among the trial’s sentinel 9–12-
year-old age-group. In the screening phase, S. mansoni in-
fection was detected by duplicate Kato–Katz thick smears13
taken from a single daily stool and S. haematobium infection
was diagnosed by the detection of microhematuria by urine
reagent strip testing.14,15
Sustaining control studies. These cluster-randomized
studies involved comparison of three different regimens of
SBT of SAC in medium prevalence communities. The har-
monized criteria for SCORE studies on sustaining control (see
protocol in Supplemental Appendix A for details) were as
follows:
FIGURE 1. Study arms and timeline for the Schistosomiasis Consortium for Operational Research and Evaluation studies of gaining and sus-
tainingcontrol of schistosomiasis in sub-SaharanAfrica.CDI=Coˆted’Ivoire;CWTorC=community-wide treatment;H=drugholiday—ayearwhen
no praziquantel mass drug administration was provided; SBT or S = school-based treatment.
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1. Community inclusion criteria
c Schistosoma infection prevalence of 10–24% (by egg de-
tection) among children aged 13–14 years in eligibility
surveysbefore thestartof thestudy,or, forS.haematobium
studies, a 5–20% prevalence of microhematuria by reagent
strip testing. The option formicrohematuria-based surveys
for village eligibility was based on their relative ease of
performance and the rapidity of their results. The lower
5–20% cutoffs for S. haematobium prevalence estimation
by dipstick testing (versus egg count prevalence) were
chosen based on the past experience of SCORE investi-
gators working in Kenya, Zanzibar, and Niger, who had
established that only about 50–60% of light and very light
infections found by egg filtration have detectable dipstick
hematuria.16,17 For the preliminary village eligibility surveys,
but not the SCORE studies themselves, 5–20% dipstick-
positive prevalence among 13–14 year olds was taken
to indicate a moderate prevalence community, where
S. haematobium egg count prevalence was likely to be
in the 10–24% range.
c Presence of a community primary school with at least
100 children aged 9–12 years who were available for
surveillance. Adjacent communities could be combined
as an implementation unit to make up this number of
children to treat and monitor.
c Community-level assent, and willingness of parents/
guardians to provide written informed consent for indi-
vidual children’s participation. Children’s assent for
testing and praziquantel treatment.
2. Community exclusion criteria
c Communities having baseline prevalence outside the
10–24% range.
c Highrates (>10%)ofmixedS.mansoniandS.haematobium
infection.
3. The primary outcomes of the study were the prevalence
and intensity of infection among a random sample of 100
local SAC, aged 9–12 years in Year 5, after 4 years of
implementation of the community’s assigned treatment
schedule.
4. As shown in Figure 1, the three study arms for comparison
were as follows: Arm 1, annual SBT for 4 years; Arm 2,
annual SBT for 2 years, followed by 2 years without prazi-
quantel treatment (praziquantel holiday years); and Arm 3,
two rounds of SBT given every other year, starting in Year 1,
with praziquantel holidays in the intervening years (years 2
and 4).
5. Primary statistical analysis focused on comparing the
WHO-recommended intervention, that is, every-other-
year MDA,9,18 to more aggressive annual treatment, or to
the impact of two annual treatments followed by a 2-year
pause.
6. Data collected for secondary analyses were focused on
community-level factors related to treatment response and
the relative costs involved in implementing each study arm.
These factors included information on local water and
sanitation features, interval rainfall and drought, and the
treatment coverage achieved among SAC in each com-
munity. In addition to monitoring 9–12-year-old children,
the prevalence and intensity of infection among 100 first-
year schoolchildren (aged 5–8 years) was assessed in the
first and fifth year of each study as an indirect gageof recent
rates of local transmission.
Gaining control studies. These cluster-randomized stud-
ies involved comparison of six different regimens of CWT
and/or SBT in communities with baseline infection prevalence
³ 25%. The harmonized criteria for SCORE studies on gaining
control were as follows:
1. Community inclusion criteria
c Schistosoma infection prevalence of ³ 25% (by egg de-
tection) among children aged 13–14 years in eligibility
surveys performed before the start of the study, or, for
S. haematobium studies, a ³ 21% prevalence of micro-
hematuria on reagent strip testing.
c School size and participation criteria as for sustaining
control studies, described earlier.
2. Community exclusion criteria
c Communities having baseline prevalence below 25%
c High rates (> 10%) of mixed S. mansoni and S. haema-
tobium infection.
3. As in the sustaining control studies, the primary study
outcomes were the prevalence and intensity of infection
among a random sample of local 9–12-year-old children in
Year 5, after 4 years of implementation of the community’s
assigned treatment schedule.
4. As shown in Figure 1, the six study arms included in gaining
control studies were as follows: Arm 1, CWT annually for 4
years; Arm 2, CWT annually for 2 years followed by SBT for 2
years; Arm 3, CWT for 2 years followed by two praziquantel
holiday years; and Arms 4–6 were identical to Arms 1–3 of
the sustaining control studies, described earlier.
5. Primary statistical analysis focused on comparing theWHO
standard of care (SBT every year, given when baseline SAC
prevalence is ³ 50%) or every-other-year MDA (when
baseline prevalence is 10–49%)9,18 to more aggressive
CWT for 2 or 4 years, or to CWT tapering to SBT over 4
years.
6. As was performed for the sustaining control studies, data
collected for secondary analyses included assessment of
community-level factors related to treatment response,
treatment coverage, and the relative costs involved in
implementing each study arm. Theprevalence and intensity
of infection were also assessed in 100 previously untreated
5–8-year-old first-year students in each community as an
indicator of ongoing transmission. For these gaining control
studies, 50 adults aged 20–55 years in each community
were also examined in years 1 and 5 both to gage the in-
fluence of baseline adult infection status on local response
to treatment intervention and assess the direct or indirect
impact of 4 years of local MDA implementation on the adult
levels of infection in the final year (Year 5).
Power analysis performed during development of the
harmonized protocols indicated that the inclusion of 25
communities in each study arm, with monitoring of 100
children per community, would have 90%power to detect a
significant (two-tailed α = 0.05) between-arm difference of
11% and 9% in the Year 5 outcomes for gaining and sus-
taining studies, respectively. The assumed overdispersion
factor was f = 5.0, and the expected prevalence shift
was from an average 50% prevalence in Year 1, to 15%
prevalence in Year 5 in gaining control studies and from
24% to 10% in sustaining control studies.1 The final se-
lection of 25 communities per arm per study was based on
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these projections and also the practical limitations (pro-
gram capacity for implementation) of proposed partner
sites in endemic countries.
Additional operational research on morbidity control was
layered onto these gaining control studies. Cohort morbidity
studies on the impact of treatment on early childhood mor-
bidity were embedded in 8–12 communities in each of the
S. haematobium and S. mansoni gaining control studies.10
Their results are described in further detail in a separate article
in this issue.19 A subset of communities in the gaining control
studies were also used for the companion studies of in-
termediate host snail abundance and infection20 and the in-
fluence of MDA on population genetics of the respective
Schistosoma parasites.21
Midpoint structural reorganization of the Niger gaining
and sustaining control studies. In the gaining and sustaining
control studies in Niger, there was a significant protocol de-
viationwith respect to randomization of study communities, in
which geographically clustered groups of 25 communities
were randomly assigned to each of the study arms rather
than having the different community interventions distributed
randomly.
Subsequently, the Niger protocols weremodified after Year
2. The new objective was to compare twice-yearly treat-
ment to once-yearly treatment. In Year 3, all study arms for
both studies were divided into two parts, with half of the
communities in each category randomized to receive sub-
sequent twice-a-year (biannual) MDA, whereas the other
half received annual MDA (see Figure 2). This created three
distinct randomized comparison sub-studies. Sub-study A
was derived from communities initially enrolled in the Niger
sustaining control study, and sub-studies B and C were
derived from communities initially enrolled in the gaining
control study. The sub-studies A, B, and C were analyzed
separately.
1. Primary outcomes of the study were the prevalence and in-
tensity of Schistosoma infection among a random sample
of local SAC, aged 9–12 years, in Year 5, after 4 years of
implementation of the community’s assigned treatment
schedule.
2. Data collected for secondary analysis was the same as for
the other studies of gaining and sustaining control. As in
those studies, the prevalence and intensity of infection was
additionally assessed in 100 first-year students in years 1
and 5. In those communities that were initially part of the
gaining control study, data were also collected on 50 adults
aged 20–55 years in years 1 and 5.
KEY FINDINGS FROM THE GAINING AND SUSTAINING
CONTROL STUDIES
In aggregate, the large-scale SCORE gaining and sus-
taining studies provided important new evidence on pro-
grammatically critical issues relating to how best to gain and
sustain the morbidity control of schistosomiasis. Mass drug
administration with praziquantel reduced community-level
prevalence and the mean intensity of Schistosoma infection
across all study arms and in all SCORE study countries (AE
Phillips, et al., personal communication and MOuattara et al.,
personal communication).22–28 Figure 3 shows the Year 1
(baseline) and Year 5 prevalence values by treatment study
arm for the sustaining control studies for S. mansoni in Coˆte
d’Ivoire and Kenya, the gaining control studies for S. mansoni
in Kenya and Tanzania, and the gaining control study for
S. haematobium in Mozambique. Prevalence by intensity of
FIGURE 2. Revised study design for Schistosomiasis Consortium for Operational Research and Evaluation’s Niger Schistosoma haematobium
control studies. CWT or C = community-wide treatment; H = drug holiday—a year when no praziquantel mass drug administration (MDA) was
provided; SBT or S = school-based treatment; x1 = one MDA per year in years 3 and 4; x2 = two MDAs per year in years 3 and 4.
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infection (light, moderate, or heavy)9 are also indicated in
Figure 3. Arms 3 (CCHH) and 5 (SSHH) in gaining control
studies and Arm 2 (SSHH) in sustaining control studies in-
volved skipping two consecutive years of praziquantel MDA
as drug holidays. When compared with arms that had four
annual treatments, those arms with alternate or consecutive
holiday years had smaller reductions in prevalence in Coˆte
d’Ivoire, Tanzania,Mozambique, andKenya (seeSupplemental
Tables S1–S5). However, because of wide variability in indi-
vidual community responses to their assigned MDA program,
this apparent disadvantage of scheduled holidays was not
statistically significant overall.
Prevalence of moderate and heavy infections declined
among 9–12-year-old children in all study arms for all gaining
and sustaining control studies. Figure 4 demonstrates the
change in community-level mean infection intensity from
Year 1 to Year 5 in the various studies.
Although there were initial reductions in response to MDA
implementation, which accord with projections of pre-study
deterministic modeling,29 the trajectories of aggregate preva-
lence and intensity impact tended to plateau after 2–3 years in
most settings.30 We observed some larger-than-expected
variations in the response of individual communities to MDA
implementation, which we refer to as persistent hot spots.23,31
FIGURE 3. Overall prevalence, by infection categories of light, moderate, and heavy intensity categories at Year 1 (baseline; Y1) and Year 5 (study
endpoint; Y5) in the Schistosomiasis Consortium for Operational Research and Evaluation gaining and sustaining control studies. The study arms
indicated are detailed in Figure 1. CDI = Coˆte d’Ivoire; C = community-wide treatment; H = drug holiday—a year when no praziquantel mass drug
administration was provided; KEN = Kenya; MOZ = Mozambique; S = school-based treatment; TAN = Tanzania.
FIGURE 4. Mean community-level infection intensity in Schistosoma mansoni eggs per gram feces, or S. haematobium eggs per 10 mL urine at
Year 1 (baseline; Y1) and Year 5 (study endpoint; Y5) in the Schistosomiasis Consortium for Operational Research and Evaluation gaining and
sustaining control studies. The study arms indicated are detailed in Figure 1. CDI = Coˆte d’Ivoire; C = community-wide treatment; H = drug
holiday—a year when no praziquantel mass drug administration was provided; KEN = Kenya; MOZ = Mozambique; S = school-based treatment;
TAN = Tanzania.
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This phenomenon is discussed in greater detail in Article 3 of
this supplement.32 The high degree of variance in response
within each study arm meant that although there were, on
average, large differences in prevalence and intensity impact
(up to 40–60%) between study arms, in our protocol’s primary
study outcomes analysis, which was specified before study
completion (see Supplement File S2 for details), the between-
arm differences in prevalence and intensity effects were not
statistically significant. Hence, there was no significant differ-
ence between the various schedules of coverage and delivery
for MDA. Supplemental Tables S1–S5 in the Supplemental
Material files provide the adjusted prevalence ratios and ad-
justed mean intensity ratios for the arm-to-arm comparisons in
each of the SCORE gaining and sustaining studies. The very
large intraclass correlations (40%) observed in our studies
mean that, if similar studies are performed in the future, it will be
necessary to have a much higher number of villages per arm
and fewer arms, or a completely different approach, such as a
village-by-village evaluation of outcomes.
Additional analysis of the gaining and sustaining
control studies.Our identification of persistent hot spots as a
potential cause of limited overall response to MDA led us to
perform an exploratory secondary analysis of community-
level features that might explain the location-specific differ-
ences in outcomes. Baseline prevalence at the onset of
intervention was different from community to community.
However, this factor did not predict prevalence or intensity of
infection in Year 5 (see Kittur et al.,32 in this supplement, and
FIGURE 5. Impact on prevalence of four consecutive years of school-based treatment (SSSS) on 9–12-year-old and first-year schoolchildren in
Schistosomiasis Consortium for Operational Research and Evaluation sustaining control studies. Baseline (Y1) and endpoint (Y5) prevalence of
Schistosomamansoni infection intensity categories are shown.Asterisks denote statistically significant differencesbetweenbaseline and endpoint
values at a P < 0.05 level by χ2 testing. CDI = Coˆte d’Ivoire; KEN = Kenya; NS = not significant.
FIGURE 6. Impact on prevalence of four consecutive years of school-based treatment (SBT or SSSS) or four consecutive years of community-
wide treatment (CWT or CCCC) on 9–12-year-old and first-year schoolchildren in Schistosomiasis Consortium for Operational Research and
Evaluation gaining control studies. Baseline (Y1) and endpoint (Y5) prevalence of Schistosoma mansoni or Schistosoma haematobium infection
intensity categories are shown. Asterisks denote statistically significant differences between baseline and endpoint values at a P < 0.05 level by χ2
testing. KEN = Kenya; MOZ = Mozambique; NS = not significant; TAN = Tanzania.
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Wiegand et al.,23). Reported community-level MDA coverage
was also not a good predictor of Year 5 outcomes.33 The use
of openor unimprovedwater supplies, close proximity to open
water sources, available sanitation (school or home latrines or
toilets), and the practice of open defecation did not predict the
odds of a community being a persistent hot spot (Musuva RM
et al., personal communication). Geospatial clustering was
observed for persistent hot spots in western Kenya,23 but not
in Tanzania or Mozambique. Because the basic village in-
ventory data collected during the SCORE treatment inter-
ventions were not revealing, SCORE has now sponsored
follow-up “village factors” study in a matched subset of hot
spot versus responder communities in Kenya and Tanzania to
probe the community characteristics of hot spots in greater
detail. Results of these surveys are pending, but we hope to
identify the most influential local factors leading to poor re-
sponse to MDA.
In its 2012–2020 Strategic Plan, the WHO recommended
the following schistosomiasis targets: 1) morbidity control by
reducing local prevalence of heavy Schistosoma infections
to < 5%and2) “elimination as apublic health problem” (EPHP)
by reducing the prevalence of heavy infections to < 1%. Re-
markably, as we took the SCORE MDA implementation to
scale, we found that many (52–66%) of the higher prevalence
communities alreadymet these criteria formorbidity control or
for EPHP at implementation baseline, that is, before any MDA
had been delivered. On the other hand, many persistent hot
spot communitieswere unable to achieve theWHO targets for
morbidity control despite 4 years of annual MDA with high
levels of treatment coverage.
The use of local informants for collection of community-
level data on environmental factors related to transmission,
including issues such as water and sanitation, proved in-
consistent. Similarly, we had concerns about reported treat-
ment coverage data, which were not found to be helpful in
explaining the overall results or the emergence of persistent
hot spots. Details about these data are found in articles by
Binder et al.,34,35 in this supplement.
ImpactofMDAonprevalenceand intensityofSchistosoma
infection in first-year students and adults. Earlier dynamic
modelshadsuggested that targetedmass treatmentofSAC (who
harbormost of the heavy-intensity infections in a typical endemic
community) should reduce the force of local Schistosoma trans-
mission in proportion to the reductions in overall egg output (i.e.,
reductions in community-levelmean egg counts).36–38 Therefore,
we looked for evidence of MDA-related changes in local force of
transmissionbymonitoring the levels of infection among younger
children (first-year school entrants aged 5–8 years) and among
adults aged 20–55 years in communities in gaining control stud-
ies, comparing baseline values to those observed in Year 5.
The impact of 4 years of SBT on the nontarget incoming first-
year students in sustaining control studies was minimal, with
only a statistically significant decrease in heavy infections in
Coˆte d’Ivoire and no impact on those in Kenya (Figure 5). By
contrast, in areas of high prevalence that received 4 years of
SBT (Figure 6, top row), a more consistent, although not uni-
form, impactwas seenon the incoming first-year students,with
a statistically significant decrease ineither total prevalenceand/
or prevalence of heavy infection. In parallel, in areas of high
prevalence that received 4 years ofCWT (Figure 6, bottom row),
FIGURE 7. Impact of four consecutive years of school-based treatment (SBT or S; Arm 4) or four consecutive years of community-wide treatment
(CWT or C; Arm 1) on 9–12-year-old children and adults in Schistosomiasis Consortium for Operational Research and Evaluation gaining control
studies. Baseline (Y1) and endpoint (Y5) prevalence ofSchistosomamansoni infection intensity categories are shown. Asterisks denote statistically
significant differences between baseline and endpoint values at a P < 0.05 level by χ2 testing. KEN = Kenya; MOZ = Mozambique; NS = not
significant; TAN = Tanzania.
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the prevalence and prevalence of heavy infections were sig-
nificantly lower in the nontarget, younger age-group.
The gaining control studies also evaluated adults aged
20–55 years at the beginning and end of the 5-year study
period. In arms that received 4 years of CWT, a modality that
included adults in the MDA, both overall prevalence and
prevalence of heavy infectionswere significantly reduced in all
studies (Figure 7, bottom row). In arms that received 4 years of
SBT only, where MDA did not include adults, the effects on
adults varied by study (Figure 7, top row). In the Kenya gaining
control study, the overall prevalence and prevalence of heavy
infections were significantly reduced among adults in both
SBT andCWTarms, indicating that 4 years of SBTwas almost
as effective as 4 years of CWT in reducing schistosome in-
fection in the local adult population. By contrast, in Tanzania
and Mozambique, SBT alone did not reduce schistosome in-
fection in adults.
Niger study results. As shown in Figure 8, biannual SBT
treatment was found to be significantly more effective for re-
ducing active schistosome infection than annual SBT in higher
prevalence areas (Arm B1 versus B2, defined in Figure 2).
However, there was no significant effect of increased treat-
ment frequency in areas with low starting prevalence (Arm A1
versus A2), or in higher prevalence areas that received CWT
instead of SBT (Arm C1 versus C2).
SUMMARY AND PUBLIC HEALTH IMPLICATIONS
To define the effectiveness and test the limitations of current
WHO-recommended schistosomiasis control protocols,9,18 the
SCORE gaining and sustaining operational research projects
performed randomizedpragmatic trials that compared the impact
of different schedules and coverage levels of praziquantel MDA.1
This field researchwas implemented on amuch larger scale than
any previous trials and under circumstances that would closely
mirror implementation of MDA in national control programs. Al-
though there were limitations to the study designs39 and perfor-
mance,34 the results from all studies confirm the following:
1. Across all treatment schedules (study arms), MDA with
praziquantel significantly reduced local Schistosoma in-
fection prevalence and infection intensity among SAC.
2. Evidence from some study locations suggested that out-
comes in locations receiving four annual rounds of MDA
were better than those in communities that skipped years
(i.e., only treated twice in 4 years).28 This effect was ob-
scuredby thewider-than-expected variation in community-
level response to MDA, unmasking the persistent hot spot
phenomenon.23,33
3. Because individual community responses to standardMDA
implementation were so highly variable, with many persis-
tent hot spots, it was likely that some communities did not
get the full benefits expected from MDA implementation.
Therefore, for optimalMDA results, there is a need to identify
persistent hot spots quickly,30 well before the 5–6 years
currently recommended for treatment impact assessment in
the current WHO strategies.40 For now, we would recom-
mend at least annual SBT MDA to start, with earlier (Year 3)
impact assessments, with ramp up of MDA performance,
and nondrug interventions where needed.30
4. Although untreated adult populations have been identified as a
potential source for persistence of transmission,41 the SCORE
gaining control studies found that the results obtained by
broadening population coverage (i.e., CWT versus SBT) were
not better than those obtained with well-implemented SBT.
Therewas evidence that in somemoderate-to-high prevalence
settings (Kenya, Mozambique, and Niger), SBT may have re-
duced infection levels among adults and new school entrants
through indirect effects on local force of transmission (Phillips
AE, et al., personal communication).24,28,30
5. None of the MDA schedules evaluated in the gaining and
sustainingcontrol studies led toeliminationof infection, even
in those communities that started at lower prevalence in the
sustaining control studies. Therefore, it is likely that future
programs aiming for elimination of transmission will need to
add extra nondrug interventions (e.g., snail control, im-
provement in water, sanitation and hygiene, and behavior
change interventions) to achieve that next stage of control.
These findings have been discussed in detail with the WHO
NTD policy makers, BMGF, and other governmental and non-
governmental NTD control partners to aid in formulation of the
next generation of schistosomiasis control and elimination
guidelines.
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